CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Earnings To Watch: Recursion Pharmaceuticals Inc (RXRX) Q2 2026 -- GF Value Sees 43% Upside

EarningsNeutral
AI Analysis

Summary

Recursion Pharmaceuticals (RXRX) Q2 2026 earnings are being watched, with analyst GF Value seeing 43% upside potential in the stock.

Importance:3/10
Sentiment:
0.00
earningsQ2 2026valuation
Related Companies

Read the original article

Published by yahoo_finance on August 4, 2026 1:39 PM

Read Original